Paying $3B: GSK tops US criminal, civil settlements for off-label, other schemes
This article was originally published in Scrip
Beating the competition is the name of the game in business. But GlaxoSmithKline's $3 billion settlement with the US government to resolve criminal and civil charges – topping rival New York-based Pfizer's $2.3 billion deal – is not likely what the London drug giant had in mind for outdoing its competitors.
You may also be interested in...
Seven years after a major shift in how the company compensated its sales force, the UK major has done a U-turn and is adapting pay packages for some specialty care reps.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.